Therapeutic Response
NPM1 p.W288Cfs*12 status confers therapeutic sensitivity to Revumenib in patients with Acute Leukemias of Ambiguous Lineage.
Statements
| Source and description |
|---|
NPM1 p.W288Cfs*12 status confers therapeutic sensitivity to Revumenib in patients with Acute Leukemias of Ambiguous Lineage.
| Source and description |
|---|